The deep complementary expertise within the team provides an opportunity for PEP-Therapy to streamline all stages of drug development, from licensing, partnerships, and design of new CP&IPs to preclinical and clinical trials.
• Antoine Prestat - Co-founder & CEO
Antoine started his career as a Research Scientist in oncology at Sanofi then spent 15 years in Technology Transfer Offices and as an adviser and business developer for biotech companies.
Antoine holds an engineering degree in biology combined with an MBA.
• Jennifer Sengenès, PhD - Head of Strategy and Development
Prior to joining PEP-Therapy in 2014, Jennifer worked as a Consultant within the innovation financing division of a consulting firm, and then served as a Project Manager in a nanotech start-up. She has a 12 years experience in project management, innovation strategy and financing, and start-up development.
Jennifer holds an engineering degree in chemistry, a PhD in molecular biology combined with an MBA.
• Laura Dadon, PharmD - Head of Regulatory Affairs & Development
Previously working in Regulatory Affairs at Shire before joining PEP-Therapy in 2018 - 3 years of experience in Regulatory Affairs management, Preclinical and Clinical Drug Development.
Pharm D completed with a Master in Pharmaceutical Biotechnology and Innovative Therapy.
• Didier Decaudin, MD, PhD - Co-founder and scientific advisor
Department of Medical Oncology at Institut Curie & Head of the Laboratory of Preclinical Investigation (LIP) in the Department of Translational Research.
• Fariba Némati, PhD - Co-founder and scientific advisor
Research Engineer in the LIP at Institut Curie. Expertise in Patient-Derived Xenografts (PDXs) and pharmacology.
• Angelita Rebollo, PhD - Co-Founder and scientific advisor
Research Director at Centre d’Immunologie et des Maladies Infectieuses (CIMI, Inserm/UPMC/CNRS). Expertise in apoptosis and in the design of Cell Penetrating & Interfering Peptides.
Board of Directors
• Antoine Prestat - Co-founder & CEO
Antoine started his career as a Research Scientist in oncology at Sanofi then spent 15 years in Technology Transfer Offices and as an adviser and business developer for biotech companies. Antoine holds an engineering degree in biology combined with an MBA.
• Philippe Tramoy
Investment Director of Quadrivium 1 seed fund at Seventure Partners. Former business development manager in Europe and Israel within the biotechnology market at Rhodia Corporate, Rhodia Chirex, and Rhodia Pharma Solutions. Founder and former Managing Partner of CBDMT, a Market & Business Intelligence company.
• Bernard Majoie, PhD
Former Scientific Director and then Chairman and Chief Executive Officer of Laboratoires Fournier. Founding Chairman of La Fondation Fournier-Majoie pour l'Innovation (FFMI). He now invests in high-potential projects led by committed researcher-entrepreneurs.
• Jean-Loup Romet Lemonne, MD
Senior Advisor Global Development at Institut Pasteur, Founder and former CEO of IDM Pharma, Inc. (NASDAQ listed company, now part of Takeda Oncology).
• Michele Marzola, PhD
Michele is an experienced founder and investor in the Life science sector. He has developed and run many successful businesses, including Founder & C.E.O. at Interceptin srl , Surgica Robotica srl, XSurgical Inc.; Chairman of the Board at Angiodroid srl.; Director at Green Bone Ortho srl, WineGrid SA, Sooma Oy, ReJoint srl. He also serves as a Partner at DeBere Capital Partners in London. Michele was previously General Manager, IBM Global Services EMEA. and was Principal at Booz Alllen & Hamilton.
Michele holds an MBA from the Columbia Graduate School of Business in New York and a doctorate in mechanical engineering from the University of Bologna.
Scientific Advisory Board
• Isabelle Ray-Coquard, MD, PhD
Medical oncologist in the Comprehensive Cancer Center Leon Bérard (CLB) and Professor of Medical Oncology at University Claude Bernard Lyon I. President of the GINECO group (Groupe d’Investigateurs National des Etudes des Cancers Ovariens et du sein) and Network Director of the national observatory dedicated to rare ovarian cancer.
• Mario Campone, MD, PhD
CEO of Institut de Cancérologie de l’Ouest (ICO), Hospital Practitioner at the ICO Department of Medical Oncology, Head of the Phase I unit certified by the National Cancer Institute and breast cancer unit. Scientific Director of Cancéropôle Grand Ouest and Professor of medical oncology at the University of Angers.
• Jean Martinez, PhD
Emeritus Professor at the University of Montpellier, Full Professor of organic chemistry and Professor of medicinal chemistry. Founder and former Director of the Institut des Biomolécules Max Mousseron (IBMM) where he was Head of the Aminoacids, Peptides and Proteins Department. Previously President of the European Peptide Society. His research led to the creation of three start-ups as well as two compounds currently on the market.
• Bruno Giroux, MD, PharmD
Independent consultant with more than 35 years of experience in the field of oncology. Previously Director of clinical oncology R&D at Servier International Research Institute, then Medical Director of the Onco-Hematology Business Unit at Roche, Scientific and Medical Manager at Bioalliance, Associate Director Medical Affairs at CAC, a CRO in oncology, and Clinical Development Oncology Manager at Roche.